Independent Franchise Partners
US Equity Fund
Independent Franchise Partners Johnson & Johnson stake
total: 60
US Equity Fund JNJ trades
- Total transactions:
- 24
- New positions:
- 1
- Added:
- 5
- Reduced:
- 18
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Independent Franchise Partners holds 246,223 Johnson & Johnson (JNJ) shares with a market value of roughly $60.19M accounting for 4.07% of the overall portfolio. To date, the estimated cost basis is nearly $137.66 for "buy" trades and estimated average "sell" price is $163.35. US Equity Fund first purchased JNJ in 2019 Q3, initially acquiring about 1.00M shares. Since the initial investment in Johnson & Johnson (JNJ), US Equity Fund has made 23 more transactions.
When did Independent Franchise Partners buy Johnson & Johnson (JNJ)?
Independent Franchise Partners first invested in Johnson & Johnson (JNJ) in 2019 Q3 at the reported quarter-end price of $129.38 per share.
What's the cost basis of US Equity Fund's JNJ stake?
The estimated cost basis for Johnson & Johnson (JNJ) stake is around $137.66 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $137.66
- Weighted AVG sell price:
- $163.35
Independent Franchise Partners's historical trades in Johnson & Johnson
24 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
4.07%
|
246,223
|
$244.44
|
$60,186,750
|
-29.99% (-105,485)
|
-1.64%
|
|
2025 Q4
|
4.64%
|
351,708
|
$206.95
|
$72,785,971
|
-8.73% (-33,639)
|
-0.42%
|
|
2025 Q3
|
4.36%
|
385,347
|
$185.42
|
$71,451,041
|
-2.62% (-10,378)
|
-0.13%
|
|
2025 Q2
|
4.17%
|
395,725
|
$152.75
|
$60,446,994
|
+0.18% (+720)
|
+0.01%
|
|
2025 Q1
|
4.69%
|
395,005
|
$165.84
|
$65,507,629
|
+24.28% (+77,173)
|
+0.92%
|
|
2024 Q4
|
4.18%
|
317,832
|
$144.62
|
$45,964,864
|
-37.46% (-190,384)
|
-1.4%
|
|
2024 Q3
|
4.20%
|
508,216
|
$162.06
|
$82,361,485
|
-4.26% (-22,629)
|
-0.2%
|
|
2024 Q2
|
4.13%
|
530,845
|
$146.16
|
$77,588,305
|
-4.31% (-23,931)
|
-0.18%
|
|
2024 Q1
|
4.50%
|
554,776
|
$158.19
|
$87,760,015
|
+105.43% (+284,721)
|
+2.31%
|
|
2023 Q4
|
2.29%
|
270,055
|
$156.74
|
$42,328,421
|
-1.15% (-3,130)
|
-0.03%
|
|
2023 Q2
|
2.42%
|
$165.52
|
+2.93% (+7,773)
|
|||
|
2023 Q1
|
2.44%
|
$155.00
|
-0.20% (-540)
|
|||
|
2022 Q4
|
3.01%
|
$176.65
|
-3.07% (-8,422)
|
|||
|
2022 Q3
|
3.03%
|
$163.36
|
-19.55% (-66,695)
|
|||
|
2022 Q2
|
3.82%
|
$177.51
|
-23.27% (-103,438)
|
|||
|
2022 Q1
|
4.20%
|
$177.23
|
-9.69% (-47,714)
|
|||
|
2021 Q4
|
4.05%
|
$171.07
|
-0.06% (-312)
|
|||
|
2021 Q3
|
3.98%
|
$161.50
|
-1.90% (-9,544)
|
|||
|
2021 Q2
|
4.09%
|
$164.74
|
-0.31% (-1,554)
|
|||
|
2021 Q1
|
4.30%
|
$164.35
|
+0.35% (+1,763)
|
|||
|
2020 Q4
|
4.28%
|
$157.38
|
-0.61% (-3,076)
|
|||
|
2020 Q3
|
4.58%
|
$148.88
|
-14.39% (-84,882)
|
|||
|
2019 Q4
|
5.43%
|
$145.87
|
-41.13% (-412,050)
|
|||
|
2019 Q3
|
6.40%
|
$129.38
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.